Finch Therapeutics Group, Inc., (FNCH): Price and Financial Metrics

Finch Therapeutics Group, Inc., (FNCH): $11.45

0.05 (+0.44%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

C

Add FNCH to Watchlist
Sign Up

Industry: Biotech

Industry

NR

Ranked

#147 of 404

in industry

FNCH Price/Volume Stats

Current price $11.45 52-week high $14.26
Prev. close $11.40 52-week low $0.80
Day low $11.45 Volume 900
Day high $11.50 Avg. volume 27,165
50-day MA $11.71 Dividend yield N/A
200-day MA $5.40 Market Cap 18.39M

FNCH Stock Price Chart Interactive Chart >


Finch Therapeutics Group, Inc., (FNCH) Company Bio


Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that has completed Phase II clinical trial for the treatment of patients with recurrent Clostridioides difficile infection, as well as for the treatment of chronic hepatitis B virus. It is also developing FIN-211, an orally administered enriched consortia product candidate for use in the treatment of autism spectrum disorder; and FIN-524 and FIN-525, which are orally administered targeted consortia product candidates for the treatment of ulcerative colitis and crohn's disease. The company has collaboration and license agreements with Millennium Pharmaceuticals, Inc.; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.


FNCH Latest News Stream


Event/Time News Detail
Loading, please wait...

FNCH Latest Social Stream


Loading social stream, please wait...

View Full FNCH Social Stream

FNCH Price Returns

1-mo -5.76%
3-mo -0.43%
6-mo 536.11%
1-year 209.46%
3-year -97.49%
5-year N/A
YTD 217.17%
2023 -74.93%
2022 -95.19%
2021 N/A
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!